We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 123

Pfizer v Ranbaxy; 55.2 proceeding; October 5, 2007 - atorvastatin

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • October 25 2007

The trial judge granted prohibition in respect of one patent claiming a novel crystalline form of atorvastatin (the "crystalline form patent") and denied prohibition in respect of another patent claiming a novel process for making atorvastatin (the "process patent"

Pfizer v. Apotex

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 7 2009

The Court upheld the decision of the Prothonotary refusing further production of ANDS documents

Apotex v. Sanofi; interlocutory motion re: affidavits of documents; clopidogrel

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • February 12 2010

Both parties brought motions for further and better affidavits of documents

Pfizer v. ratiopharm, motion to amended a previous judgment on the merits

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • December 3 2009

ratiopharm was successful in the proceeding under the NOC Regulations at the trial level, but the decision was overturned on appeal

Bayer Inc. v. Canada (Health), listing decision

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • December 3 2009

The Court dismissed a judicial review of the Minister’s decision refusing to list a formulation patent on the Patent Register

Recent cases

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • August 1 2008

The Court of Appeal overturned the motions judge's decision striking the notice of appearance

Data protection: defining innovative drug in Canada

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

Canada amended its Data Protection Regulations in 2006 to provide protection for innovative drugs in a second attempt to implement Canada's 1994

Apotex v. Adir

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • July 27 2009

The Court of Appeal upheld the decision of the Trial Division finding that the patent was both valid and infringed

Federal court affirms standing for innovative drug manufacturer

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • July 23 2014

What rights do innovative drug manufacturers have in situations where generics challenge certain Health Canada decisions but do not name the

PMPRB issues discussion paper on options to address the Federal Court decision in LEO Pharma

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • February 6 2008

The Patented Medicine Prices Review Board (PMPRB) has issued a discussion paper outlining a series of options to address the implications of the Federal Court of Canada decision in the LEO Pharma case